CA1202903A - Composition stable, et sa preparation - Google Patents

Composition stable, et sa preparation

Info

Publication number: CA1202903A
Authority: CA; Canada
Prior art keywords: tdm; composition; cws; oil; percent
Prior art date: 1982-04-29
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

CA000426843A

Other languages

English (en)

Inventor

Edgar E. Ribi

Steven M. Schwartzman

John L. Cantrell

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Ribi Immunochem Research Inc

Original Assignee

Ribi Immunochem Research Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1982-04-29

Filing date

1983-04-27

Publication date

1986-04-08

1983-04-27 Application filed by Ribi Immunochem Research Inc filed Critical Ribi Immunochem Research Inc

1986-04-08 Application granted granted Critical

1986-04-08 Publication of CA1202903A publication Critical patent/CA1202903A/fr

Status Expired legal-status Critical Current

Links

239000000203 mixture Substances 0.000 title claims abstract description 44
238000002360 preparation method Methods 0.000 title description 4
238000000034 method Methods 0.000 claims abstract description 17
108010039939 Cell Wall Skeleton Proteins 0.000 claims abstract description 14
210000004520 cell wall skeleton Anatomy 0.000 claims abstract description 14
206010028980 Neoplasm Diseases 0.000 claims abstract description 12
239000000839 emulsion Substances 0.000 claims description 15
239000003599 detergent Substances 0.000 claims description 5
239000004215 Carbon black (E152) Substances 0.000 claims description 4
241000283073 Equus caballus Species 0.000 claims description 4
229930195733 hydrocarbon Natural products 0.000 claims description 4
150000002430 hydrocarbons Chemical class 0.000 claims description 4
201000001441 melanoma Diseases 0.000 claims description 4
241000283690 Bos taurus Species 0.000 claims description 3
241000282465 Canis Species 0.000 claims description 2
201000008808 Fibrosarcoma Diseases 0.000 claims description 2
206010039491 Sarcoma Diseases 0.000 claims description 2
239000012153 distilled water Substances 0.000 claims description 2
238000002156 mixing Methods 0.000 claims description 2
201000000306 sarcoidosis Diseases 0.000 claims description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
XETCRXVKJHBPMK-MJSODCSWSA-N trehalose 6,6'-dimycolate Chemical compound C([C@@H]1[C@H]([C@H](O)[C@@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](COC(=O)C(CCCCCCCCCCC3C(C3)CCCCCCCCCCCCCCCCCC)C(O)CCCCCCCCCCCCCCCCCCCCCCCCC)O2)O)O1)O)OC(=O)C(C(O)CCCCCCCCCCCCCCCCCCCCCCCCC)CCCCCCCCCCC1CC1CCCCCCCCCCCCCCCCCC XETCRXVKJHBPMK-MJSODCSWSA-N 0.000 claims 5
-1 polyoxyethylene Polymers 0.000 claims 2
229920003171 Poly (ethylene oxide) Polymers 0.000 claims 1
229920002732 Polyanhydride Polymers 0.000 claims 1
235000014113 dietary fatty acids Nutrition 0.000 claims 1
239000003995 emulsifying agent Substances 0.000 claims 1
229930195729 fatty acid Natural products 0.000 claims 1
239000000194 fatty acid Substances 0.000 claims 1
238000004519 manufacturing process Methods 0.000 claims 1
239000008194 pharmaceutical composition Substances 0.000 claims 1
229920005862 polyol Polymers 0.000 claims 1
HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 abstract description 3
HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 abstract description 3
HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 abstract description 3
238000011282 treatment Methods 0.000 abstract description 3
230000000694 effects Effects 0.000 abstract description 2
238000004108 freeze drying Methods 0.000 abstract description 2
239000003921 oil Substances 0.000 description 20
210000002421 cell wall Anatomy 0.000 description 7
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
210000004027 cell Anatomy 0.000 description 5
239000011780 sodium chloride Substances 0.000 description 5
239000002904 solvent Substances 0.000 description 5
241001465754 Metazoa Species 0.000 description 4
241001467552 Mycobacterium bovis BCG Species 0.000 description 4
239000000725 suspension Substances 0.000 description 4
241000894006 Bacteria Species 0.000 description 3
FRPHFZCDPYBUAU-UHFFFAOYSA-N Bromocresolgreen Chemical compound CC1=C(Br)C(O)=C(Br)C=C1C1(C=2C(=C(Br)C(O)=C(Br)C=2)C)C2=CC=CC=C2S(=O)(=O)O1 FRPHFZCDPYBUAU-UHFFFAOYSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
241000187480 Mycobacterium smegmatis Species 0.000 description 3
229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 3
239000002480 mineral oil Substances 0.000 description 3
235000010446 mineral oil Nutrition 0.000 description 3
239000000126 substance Substances 0.000 description 3
241000700199 Cavia porcellus Species 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
241000186227 Corynebacterium diphtheriae Species 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
241000186367 Mycobacterium avium Species 0.000 description 2
241000186363 Mycobacterium kansasii Species 0.000 description 2
241000187481 Mycobacterium phlei Species 0.000 description 2
241000187563 Rhodococcus ruber Species 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
230000000259 anti-tumor effect Effects 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
239000000463 material Substances 0.000 description 2
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
229920000053 polysorbate 80 Polymers 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
238000000638 solvent extraction Methods 0.000 description 2
PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
230000001629 suppression Effects 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
201000008827 tuberculosis Diseases 0.000 description 2
NSFMUHNGROVPRE-UHFFFAOYSA-N 7-hexyloctadecane Chemical compound CCCCCCCCCCCC(CCCCCC)CCCCCC NSFMUHNGROVPRE-UHFFFAOYSA-N 0.000 description 1
229920000189 Arabinogalactan Polymers 0.000 description 1
239000001904 Arabinogalactan Substances 0.000 description 1
241000589567 Brucella abortus Species 0.000 description 1
108090000317 Chymotrypsin Proteins 0.000 description 1
241000186216 Corynebacterium Species 0.000 description 1
241001445332 Coxiella <snail> Species 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
241000186366 Mycobacterium bovis Species 0.000 description 1
241000187678 Nocardia asteroides Species 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
241000700605 Viruses Species 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000011149 active material Substances 0.000 description 1
239000013566 allergen Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
235000019312 arabinogalactan Nutrition 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
210000003850 cellular structure Anatomy 0.000 description 1
WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
229960002376 chymotrypsin Drugs 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
206010073071 hepatocellular carcinoma Diseases 0.000 description 1
230000028993 immune response Effects 0.000 description 1
238000009169 immunotherapy Methods 0.000 description 1
239000012535 impurity Substances 0.000 description 1
238000011835 investigation Methods 0.000 description 1
238000002955 isolation Methods 0.000 description 1
230000003902 lesion Effects 0.000 description 1
229940059904 light mineral oil Drugs 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
208000021039 metastatic melanoma Diseases 0.000 description 1
244000005700 microbiome Species 0.000 description 1
JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
239000007764 o/w emulsion Substances 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
238000010898 silica gel chromatography Methods 0.000 description 1
229940032094 squalane Drugs 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
230000005760 tumorsuppression Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Molecular Biology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Microbiology (AREA)
Mycology (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicinal Preparation (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Colloid Chemistry (AREA)

CA000426843A 1982-04-29 1983-04-27 Composition stable, et sa preparation Expired CA1202903A (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US37284482A	1982-04-29	1982-04-29
US372,844		1982-04-29

Publications (1)

Publication Number	Publication Date
CA1202903A true CA1202903A (fr)	1986-04-08

Family

ID=23469853

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA000426843A Expired CA1202903A (fr)	1982-04-29	1983-04-27	Composition stable, et sa preparation

Country Status (4)

Country	Link
AU (1)	AU555085B2 (fr)
CA (1)	CA1202903A (fr)
GB (1)	GB2120548B (fr)
NZ (1)	NZ204020A (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5059518A (en) *	1988-10-20	1991-10-22	Coulter Corporation	Stabilized lyophilized mammalian cells and method of making same
US6090385A (en) *	1993-12-10	2000-07-18	Maes; Hubert	Method of treating cancer
BE1007823A3 (fr) *	1993-12-10	1995-10-31	Anda Biolog Sa	Utilisation d'une composition comprenant au moins un antigene et/ou un ou plusieurs fragments de cet antigene pour l'obtention d'un medicament destine au traitement et/ou a la prevention du cancer.
AUPO359396A0 (en) *	1996-11-13	1996-12-05	Amrad Operations Pty. Limited	A method of treatment and pharmaceutical compositions useful for same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1163470A (en) *	1967-11-13	1969-09-04	Cecil Arthur Clark	Improvements in or relating to Adjuvant Vaccines
US3932943A (en) *	1970-08-14	1976-01-20	E. I. Du Pont De Nemours And Company	Method of preparation of lyophilized biological products
US4134214A (en) *	1977-08-05	1979-01-16	Merck & Co., Inc.	Freeze-drying process for the preparation of meningococcus vaccine without degradation of potency

1983
- 1983-04-27 NZ NZ20402083A patent/NZ204020A/en unknown
- 1983-04-27 CA CA000426843A patent/CA1202903A/fr not_active Expired
- 1983-04-28 GB GB8311592A patent/GB2120548B/en not_active Expired
- 1983-04-28 AU AU14015/83A patent/AU555085B2/en not_active Ceased

Also Published As

Publication number	Publication date
GB2120548A (en)	1983-12-07
AU555085B2 (en)	1986-09-11
AU1401583A (en)	1983-11-03
GB2120548B (en)	1986-11-26
GB8311592D0 (en)	1983-06-02
NZ204020A (en)	1987-01-23

Legal Events

Date	Code	Title	Description
2003-04-27	MKEX	Expiry

Publication	Publication Date	Title
US4520019A (en)	1985-05-28	Stable composition and preparation thereof
US4877611A (en)	1989-10-31	Vaccine containing tumor antigens and adjuvants
US4436728A (en)	1984-03-13	Refined detoxified endotoxin product
US4436727A (en)	1984-03-13	Refined detoxified endotoxin product
JP2648305B2 (ja)	1997-08-27	多糖類ワクチン
US4505900A (en)	1985-03-19	Refined detoxified endotoxin product
US4435386A (en)	1984-03-06	Refined detoxified endotoxin product
US20080152738A1 (en)	2008-06-26	Formulations useful for immunotherapy for cancers containing bacterial component as an active ingredient
DE69418183T2 (de)	1999-12-16	Immunotherapeutische zubereitung
US4505899A (en)	1985-03-19	Refined detoxified endotoxin product
US4504473A (en)	1985-03-12	Pyridine soluble extract of a microorganism
JPWO2000003724A1 (ja)	2001-09-18	細菌の菌体成分を有効成分とする癌免疫療法用製剤
EP1420818B1 (fr)	2018-11-21	Compositions antigeniques
US4505903A (en)	1985-03-19	Pyridine soluble extract of a microorganism
GB2120548A (en)	1983-12-07	Anti-tumour microorganism obtained products
US4503048A (en)	1985-03-05	Pyridine soluble extract of a microorganism
CA1206416A (fr)	1986-06-24	Extrait de pyridine soluble provenant de microorganismes
CA1209504A (fr)	1986-08-12	Extrait de microorganisme soluble dans la pyridine
GB2122897A (en)	1984-01-25	Treatment of cancer with microorganism obtained products
EP0083673A1 (fr)	1983-07-20	Produits pour l'application intravasale des extraits d'organes antigéniques solubles dans l'eau ou pouvant être émulsifiées